Oncology 类别的文章 - Peeref

Article Oncology

CD8+ T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4

Peng Liao, Weimin Wang, Weichao Wang, Ilona Kryczek, Xiong Li, Yingjie Bian, Amanda Sell, Shuang Wei, Sara Grove, Jeffrey K. Johnson, Paul D. Kennedy, Miguel Gijon, Yatrik M. Shah, Weiping Zou

Summary: T cell-derived interferon gamma (IFN γ) in combination with arachidonic acid (AA) induces immunogenic tumor ferroptosis, serving as a mechanism for CD8(+) T cell-mediated tumor killing. This process involves IFN γ stimulation of ACSL4 and alteration of tumor cell lipid pattern.

CANCER CELL (2022)

添加到收藏夹

Review Oncology

Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations

Aaron C. Tan, Daniel S. W. Tan

Summary: The therapeutic landscape of non-small-cell lung cancer is undergoing significant changes with the shift from histology-based classification to molecularly defined subsets. Targeted therapies for specific driver mutations such as EGFR, ALK, and ROS1 have shown promising results, and there is a growing list of approved therapies for other mutations. The importance of diagnostic molecular testing, optimal sequencing of therapies, application of targeted therapies in early-stage disease, and the impact of genomic mutations on targeted therapy efficacy are important areas of research.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

American Cancer Society nutrition and physical activity guideline for cancer survivors

Cheryl L. Rock, Cynthia A. Thomson, Kristen R. Sullivan, Carol L. Howe, Lawrence H. Kushi, Bette J. Caan, Marian L. Neuhouser, Elisa Bandera, Ying Wang, Kimberly Robien, Karen M. Basen-Engquist, Justin C. Brown, Kerry S. Courneya, Tracy E. Crane, David O. Garcia, Barbara L. Grant, Kathryn K. Hamilton, Sheri J. Hartman, Stacey A. Kenfield, Maria Elena Martinez, Jeffrey A. Meyerhardt, Larissa Nekhlyudov, Linda Overholser, Alpa Patel, Bernardine M. Pinto, Mary E. Platek, Erika Rees-Punia, Colleen K. Spees, Susan M. Gapstur, Marjorie L. McCullough

Summary: This article discusses the impact of nutrition, physical activity, and diet on recurrence and overall survival rates among cancer survivors. It provides evidence-based recommendations for cancer survivors and highlights the importance of addressing survivors' needs through clinical care coordination and resources.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

添加到收藏夹

Review Oncology

HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management

Matt Lechner, Jacklyn Liu, Liam Masterson, Tim R. Fenton

Summary: The incidence of HPV-positive oropharyngeal squamous cell carcinoma (OPSCC) is rapidly increasing, leading to ongoing research in treatment de-escalation and emerging therapies. There is a need to identify and validate diagnostic biomarkers for early detection of this disease.

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline

Michael A. Vogelbaum, Paul D. Brown, Hans Messersmith, Priscilla K. Brastianos, Stuart Burri, Dan Cahill, Ian F. Dunn, Laurie E. Gaspar, Na Tosha N. Gatson, Vinai Gondi, Justin T. Jordan, Andrew B. Lassman, Julia Maues, Nimish Mohile, Navid Redjal, Glen Stevens, Erik Sulman, Martin van den Bent, H. James Wallace, Jeffrey S. Weinberg, Gelareh Zadeh, David Schiff

Summary: The purpose of this study is to provide guidelines for clinicians on treating patients with brain metastases from solid tumors. The study conducted a systematic review of the literature and found that surgery is a reasonable option for patients with brain metastases. Local therapy should be given to patients with symptomatic brain metastases, regardless of the systemic therapy used. For patients with asymptomatic brain metastases, local therapy should not be deferred unless specifically recommended. Several regimens were recommended for different types of cancer. For patients with no systemic therapy options, stereotactic radiosurgery (SRS) alone should be offered. Memantine and hippocampal avoidance should be considered for patients receiving whole brain radiation therapy. Patients with low Karnofsky Performance Status and no systemic therapy options do not benefit from radiation therapy.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Targeting p53 for the treatment of cancer

Michael J. Duffy, Naoise C. Synnott, Shane O'Grady, John Crown

Summary: Dysfunction of the TP53 gene is prevalent in human malignancies, making it an attractive target for new anticancer drugs. Two strategies, reactivating mutant p53 and inhibiting the interaction between wild-type p53 and MDM2/MDM4, are being explored in clinical trials. The development of compounds targeting these strategies has the potential to revolutionize cancer treatment.

SEMINARS IN CANCER BIOLOGY (2022)

添加到收藏夹

Article Oncology

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312) : a multicentre, open-label, randomised, phase 3 trial

Robin Kate Kelley, Lorenza Rimassa, Ann-Lii Cheng, Ahmed Kaseb, Shukui Qin, Andrew X. Zhu, Stephen L. Chan, Tamar Melkadze, Wattana Sukeepaisarnjaroen, Valery Breder, Gontran Verset, Edward Gane, Ivan Borbath, Jose David Gomez Rangel, Baek-Yeol Ryoo, Tamta Makharadze, Philippe Merle, Fawzi Benzaghou, Kamalika Banerjee, Saswati Hazra, Jonathan Fawcett, Thomas Yau

Summary: This study evaluated the combination of cabozantinib and atezolizumab versus sorafenib as first-line systemic treatment for advanced hepatocellular carcinoma. The combination treatment group showed better progression-free survival compared to the sorafenib group, but overall survival did not reach statistical significance. Common adverse events in the combination group included liver enzyme elevation, hypertension, and skin reactions. The study suggests that cabozantinib plus atezolizumab may be a treatment option, but further research is needed.

LANCET ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1

Do-Youn Oh, Aiwu Ruth He, Shukui Qin, Li-Tzong Chen, Takuji Okusaka, Arndt Vogel, Jin Won Kim, Thatthan Suksombooncharoen, Myung Ah Lee, Masayuki Kitano, Howard A. Burris, Mohamed Bouattour, Suebpong Tanasanvimon, Renata Zaucha, Antonio Avallone, Juan Cundom, Nana Rokutanda, Julia Xiong, Gordon Cohen, Juan W. Valle

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Exploiting senescence for the treatment of cancer

Liqin Wang, Lina Lankhorst, Rene Bernards

Summary: This review discusses how senescence can be induced in cancer cells and how the distinctive features of senescent cancer cells can be exploited for selective eradication. It also explores activation of the host immune system as an attractive way to clear senescent cancer cells, and the potential benefits of a sequential treatment approach with pro-senescence therapy followed by senolytic therapy.

NATURE REVIEWS CANCER (2022)

添加到收藏夹

Article Oncology

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

Caron A. Jacobson, Julio C. Chavez, Alison R. Sehgal, Basem M. William, Javier Munoz, Gilles Salles, Pashna N. Munshi, Carla Casulo, David G. Maloney, Sven de Vos, Ran Reshef, Lori A. Leslie, Ibrahim Yakoub-Agha, Olalekan O. Oluwole, Henry Chi Hang Fung, Joseph Rosenblatt, John M. Rossi, Lovely Goyal, Vicki Plaks, Yin Yang, Remus Vezan, Mauro P. Avanzi, Sattva S. Neelapu

Summary: This study assessed the use of axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma and found that it showed high rates of durable responses and had a manageable safety profile.

LANCET ONCOLOGY (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Targeting TGF-β signal transduction for fibrosis and cancer therapy

Dandan Peng, Minyang Fu, Manni Wang, Yuquan Wei, Xiawei Wei

Summary: TGF-beta plays essential roles in early embryonic development, organogenesis, immune regulation, tissue repair, and adult homeostasis. Its involvement in fibrosis and cancer is complex and context-dependent, showing both inhibitory and promoting effects. Therapeutics targeting TGF-beta signaling hold promise in treating fibrosis and cancer, although the development is hindered by potential systemic cytotoxicity.

MOLECULAR CANCER (2022)

添加到收藏夹

Article Oncology

Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

F. Lordick, F. Carneiro, S. Cascinu, T. Fleitas, K. Haustermans, G. Piessen, A. Vogel, E. C. Smyth, ESMO Guidelines Committee

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

A. Cervantes, R. Adam, S. Rosello, D. Arnold, N. Normanno, J. Taieb, J. Seligmann, T. De Baere, P. Osterlund, T. Yoshino, E. Martinelli

ANNALS OF ONCOLOGY (2023)

添加到收藏夹

Review Biochemistry & Molecular Biology

Exosomes as a new frontier of cancer liquid biopsy

Dan Yu, Yixin Li, Maoye Wang, Jianmei Gu, Wenrong Xu, Hui Cai, Xinjian Fang, Xu Zhang

Summary: Liquid biopsy, a revolutionary strategy for cancer diagnosis and prognosis prediction, uses minimally invasive detection through biofluids such as blood, saliva, and urine. Exosomes, a subset of extracellular vesicles, play a crucial role in intercellular communication and are considered as potential biomarkers in liquid biopsy. However, the lack of high-quality separation and component analysis methods has limited the further clinical application of exosomes.

MOLECULAR CANCER (2022)

添加到收藏夹

Article Oncology

Kidney Cancer, Version 3.2022

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Ajjai Alva, Michael Baine, Kathryn Beckermann, Maria Carlo, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Arpita Desai, Yasser Ged, Saby George, John L. Gore, Naomi Haas, Steven L. Hancock, Payal Kapur, Christos Kyriakopoulos, Elaine T. Lam, Primo N. Lara, Clayton Lau, Bryan Lewis, David C. Madoff, Brandon Manley, M. Dror Michaelson, Amir Mortazavi, Lakshminarayanan Nandagopal, Elizabeth R. Plimack, Lee Ponsky, Sundhar Ramalingam, Brian Shuch, Zachary L. Smith, Jeffrey Sosman, Mary A. Dwyer, Lisa A. Gurski, Angela Motter

Summary: The NCCN Guidelines for Kidney Cancer provide comprehensive treatment recommendations for renal cell carcinoma, covering screening, diagnosis, staging, surgery, and systemic therapy. Tumor histology and risk stratification of patients are important factors in treatment selection, considering efficacy, safety, evidence, and accessibility of agents.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2022)

添加到收藏夹

Article Oncology

Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

T. Powles, J. Bellmunt, E. Comperat, M. De Santis, R. Huddart, Y. Loriot, A. Necchi, B. P. Valderrama, A. Ravaud, S. F. Shariat, B. Szabados, M. S. van der Heijden, S. Gillessen

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

The role of m6A RNA methylation in cancer metabolism

Yuanyuan An, Hua Duan

Summary: Metabolic reprogramming is a key characteristic of malignant tumors. The modification of m6A RNA methylation plays a crucial role in the regulation of tumor cell metabolism.

MOLECULAR CANCER (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments

Saife N. Lone, Sabah Nisar, Tariq Masoodi, Mayank Singh, Arshi Rizwan, Sheema Hashem, Wael El-Rifai, Davide Bedognetti, Surinder K. Batra, Mohammad Haris, Ajaz A. Bhat, Muzafar A. Macha

Summary: Liquid biopsies are non-invasive methods that have revolutionized cancer diagnosis and monitoring. By analyzing tumor-derived entities in body fluids, liquid biopsies provide detailed information about tumor characteristics and can be used for detection, prognosis, and treatment monitoring.

MOLECULAR CANCER (2022)

添加到收藏夹

Article Oncology

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Luis G. Paz-Ares, Suresh S. Ramalingam, Tudor-Eliade Ciuleanu, Jong-Seok Lee, Laszlo Urban, Reyes Bernabe Caro, Keunchil Park, Hiroshi Sakai, Yuichiro Ohe, Makoto Nishio, Clarisse Audigier-Valette, Jacobus A. Burgers, Adam Pluzanski, Randeep Sangha, Carlos Gallardo, Masayuki Takeda, Helena Linardou, Lorena Lupinacci, Ki Hyeong Lee, Claudia Caserta, Mariano Provencio, Enric Carcereny, Gregory A. Otterson, Michael Schenker, Bogdan Zurawski, Aurelia Alexandru, Alain Vergnenegre, Judith Raimbourg, Kynan Feeney, Sang-We Kim, Hossein Borghaei, Kenneth John O'Byrne, Matthew D. Hellmann, Arteid Memaj, Faith Ellen Nathan, Judith Bushong, Phuong Tran, Julie R. Brahmer, Martin Reck

Summary: Nivolumab plus ipilimumab continues to demonstrate durable long-term efficacy in patients with advanced NSCLC, with a significant improvement in overall survival compared to chemotherapy. Immune-mediated adverse events occur early but can be managed with guideline-based treatment. Discontinuation of nivolumab plus ipilimumab due to adverse events does not impact the long-term benefits seen in all randomized patients.

JOURNAL OF THORACIC ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Predicting cancer outcomes with radiomics and artificial intelligence in radiology

Kaustav Bera, Nathaniel Braman, Amit Gupta, Vamsidhar Velcheti, Anant Madabhushi

Summary: The successful use of artificial intelligence in oncology imaging for diagnostic purposes has prompted the exploration of its potential in addressing more complex clinical needs. This perspective discusses the evolution of AI tools in oncology imaging, focusing on challenges such as outcome prognostication across multiple cancers and response prediction to various treatment modalities. The authors also highlight the opportunities and challenges in the path to clinical adoption, aiming to demystify AI for clinicians and emphasize its role as a decision-support tool in cancer management.

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

添加到收藏夹

«
1
2
3
4
5
»

See full results

Related Categories

Anesthesiology (212.5K) Audiology & Speech-Language Pathology (1.7K) Clinical Neurology (1.3M) Critical Care Medicine (338.4K) Dentistry, Oral Surgery & Medicine (340.8K) Dermatology (413.6K) Emergency Medicine (142.9K) Endocrinology & Metabolism (751.7K) Gastroenterology & Hepatology (856.4K) Geriatrics & Gerontology (226.3K) Gerontology (158.2K) Health Care Sciences & Services (433.8K) Hematology (653.3K) Immunology (896.7K) Infectious Diseases (453.2K) Integrative & Complementary Medicine (99.8K) Medical Ethics (26.6K) Medical Informatics (100.5K) Medical Laboratory Technology (108K) Medicine, General & Internal (1.3M) Medicine, Legal (48.4K) Medicine, Research & Experimental (710K) Nursing (297.8K) Obstetrics & Gynecology (559.8K) Ophthalmology (452.2K) Orthopedics (359.5K) Otorhinolaryngology (166K) Pediatrics (655.3K) Peripheral Vascular Disease (595.7K) Pharmacology & Pharmacy (1.3M) Primary Health Care (59.2K) Psychiatry (755.1K) Radiology, Nuclear Medicine & Medical Imaging (799.4K) Rehabilitation (249.2K) Rheumatology (300.3K) Surgery (1.3M) Toxicology (333.1K) Transplantation (309.7K) Tropical Medicine (112.2K) Urology & Nephrology (567K) Veterinary Sciences (455.3K)

© Peeref 2019-2024. All rights reserved.